Here are four things to know.
1. OsteGro is developed with Aziyo’s proprietary processing methods, resulting in a bone graft that acts as a scaffold for new bone growth. The matrix is regulated as a human tissue allograft.
2. Composed of cancellous bone and partially demineralized cortical bone, OsteGro is designed to be easily molded to produce the desired shape. It is sterile and can be stored at room temperature.
3. OsteGro is the third product in Aziyo’s portfolio, which includes ViBone, a viable bone matrix, and OsteSpine, a complete line of precision machined cervical spacers.
4. The biologics segment of the U.S. orthopedic market is estimated to total approximately $2 billion in sales annually.
More articles on biologics:
5 key vendors in the global stem cell therapy market
KICVentures acquires Amend Surgical to enhance biologics portfolio: 5 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
